Endometrial cancer (EC) remains one of the most common gynecologic malignancies worldwide. However, the exact etiology is still unknown. Human Zinc ribbon domain containing 1 (ZNRD1) was involved in carcinogenesis and progression of multiple cancers, including EC.
ZNRD1-AS1, a long noncoding RNA (lncRNA) located in the upstream of ZNRD1, has been reported as an essential component in carcinogenesis.
However, the underlying relations of ZNRD1-AS1 with development of EC remain obscure. This study aims to evaluate the potential role of ZNRD1-AS1 and Cis-eQTL loci of ZNRD1 in the occurrence of EC.
We first evaluated the expression of ZNRD1-AS1 and ZNRD1 among EC tissues and corresponding normal tissues using quantitative Real Time-Polymerase Chain Reaction (qRT-PCR).
Then, to reveal the underlying mechanisms, we investigated the associations between Cis-eQTL loci of ZNRD1 in ZNRD1-AS1 and the susceptibility of EC.
Further, in vitro experiments were conducted to evaluate the regulation role of rs9261204 on the expression of ZNRD1gene.Higher expression of ZNRD1-AS1 and lower expression of ZNRD1 were detected in the EC tissues, compared to the normal tissues. Minor allele of rs9261204 was significantly associated with increased risk of EC (OR: 1.33; 95% CI: 1.09-1.61; p = 0.004).
Furthermore, in vitro experiments confirmed that Ishikawa cells with rs9261204 G allele had lower mRNA level of ZNRD1, compared to the A allele.Our findings first showed the contribution of LncRNA ZNRD1-AS1 and Cis-eQTL loci of ZNRD1 to the development of EC. Further studies incorporating larger populations and functional assays are warranted.
Impact of polymorphisms in the HCP5 and HLA-C, and ZNRD1 genes on HIV viral load.
Single nucleotide polymorphisms (SNPs) in the human leucocyte antigen (HLA) complex P5 (HCP5), HLA-C, and near the zinc ribbon domain containing 1 (ZNRD1) have been shown to influence viral load (VL) set point in HIV-infected individuals with a known seroconversion onset.
We aimed to determine the influence of HCP5 rs2395029, HLA-C rs9264942, and ZNRD1 rs3869068 on VL in antiretroviral-naïve individuals and on time to the first VL<51 copies/ml and on CD4(+) T-cell recovery after initiation of combination antiretroviral therapy (cART).
We genotyped the rs2395029 (A>C), rs9264942 (T>C), and rs3869068 (C>T) SNPs in 1897 Caucasians from The Danish HIV Cohort Study – a prospective, nationwide, population-based study of HIV-infected individuals in Denmark.
General linear models evaluated the effect of SNPs on VL in antiretroviral-naïve individuals 0-18months after diagnosis and on CD4(+) T-cell recovery during cART. Cox proportional hazard regression analysis assessed the association with time to first VL<51 copies/ml.
All models were assuming additive genetic effects.
The rs2395029, rs9264942, and rs3869068 minor alleles were associated with lower VL in antiretroviral-naïve individuals (rs2395029: [mean VL (copies/ml)], A/A: 70,795 [61,660-79,433], A/C: 33,884 [19,498-58,884], P=0.002; rs9264942: TT: 81,283 [67,608-97,724], T/C: 63,096 [54,954-75,858], CC: 38,905 [25,119-58,884], P<0.0001; rs3869068, CC: 72,444 [63,096-83,176], C/T: 45,709 [33,113-64,565], TT: 58,884 [20,417-169,824], P=0.01). Moreover, the C-alleles of rs2395029 and rs9264942 were associated with shorter time to VL<51 copies/ml: (HR [95% confidence interval], 1.67 [1.09-1.72], P=0.008; 1.16 [1.06-1.28], P=0.002; 1.30 [1.08-1.53], P=0.005, respectively, adjusted for last VL before cART). None of the SNPs predicted CD4(+) T-cell recovery during cART.
The minor alleles of rs2395029, rs9264942, and rs3689068 associate with lower VL among antiretroviral-naïve individuals and with shorter time to first VL<51copies/ml during cART even after adjustment for VL before cART.
Single nucleotide polymorphisms in ZNRD1-AS1 increase cancer risk in an Asian population.
Single nucleotide polymorphisms (SNPs) in human zinc ribbon domain containing 1 antisense RNA 1 (ZNRD1-AS1) have been associated with cancer development. In this meta-analysis, we more precisely estimated the associations between three expression quantitative trait loci SNPs in ZNRD1-AS1 (rs3757328, rs6940552, and rs9261204) and cancer susceptibility.
The data for three SNPs were extracted from eligible studies, which included 5,293 patients and 5,440 controls. Overall, no significant associations between SNPs in ZNRD1-AS1 (rs3757328, rs6940552, and rs9261204) and cancer risk were observed.
However, in further subgroup analyses based on cancer type, we found that the A allele of rs3757328 increased the risk of some cancer in both allele contrast (OR = 1.15, 95% CI = 1.05 – 1.25) and recessive models (OR = 1.79; 95% CI = 1.33 – 2.41).
The A allele of rs6940552 and the G allele of rs9261204 also increased the risk of some cancer in an Asian population in allele contrast (OR = 1.17, 95% CI = 1.08 – 1.26, and OR = 1.25, 95% CI = 1.16 – 1.34, respectively) and recessive models (OR = 1.44, 95% CI = 1.18 – 1.77, and OR = 1.49; 95% CI = 1.23 – 1.80, respectively). Thus, rs3757328, rs6940552, and rs9261204 in ZNRD1-AS1 are all associated with increased some cancer risk in an Asian population.
Hepatitis B virus genotypes, expression quantitative trait loci for ZNRD1-AS1 and their interactions in hepatocellular carcinoma.
Genetic variants in zinc ribbon domain-containing 1 antisense RNA 1 (ZNRD1-AS1) have been reported to be associated with development of hepatocellular carcinoma (HCC).
We sought to determine the influences of ZNRD1-AS1 polymorphisms and their interactions with Hepatitis B virus (HBV) genotypes on the risk of HCC.
In this study, we conducted a large population case-control study with 1,507 HBV-related HCC cases and 1,560 HBV persistent carriers.
Three single-nucleotide polymorphisms (SNPs) in ZNRD1-AS1 (rs3757328, rs6940552 and rs9261204) were genotyped using a TaqMan allelic discrimination assay, and the HBV genotypes were identified by multiplex PCR.
We found consistently significant associations between the ZNRD1-AS1 rs6940552 and rs9261204 SNPs with an increased risk of HCC (additive genetic model: adjusted OR = 1.16, 95% CI = 1.03-1.32 for rs6940552; adjusted OR =1.20, 95% CI = 1.06-1.35 for rs9261204) and found a borderline association between rs3757328 and HCC risk. Besides, we observed a dose-dependent relationship between increasing numbers of variant alleles of the SNPs and HCC risk (P for trend <0.001).
Moreover, we observed a stronger combined effect of the three SNPs on HCC risk among the subjects infected with non-B genotype HBV (adjusted OR = 1.26, 95% CI = 1.05-1.50) compared with HBV B-related genotypes (adjusted OR = 0.89, 95% CI = 0.69-1.15; P= 0.029 for heterogeneity test).
We also found that a multiplicative interaction between the variant alleles and the HBV genotype significantly affected HCC susceptibility (P = 0.030).
Together, these results indicate that ZNRD1-AS1 may influence HCC risk accompanied by HBV genotypes.
Strong evidence for LncRNA ZNRD1-AS1, and its functional Cis- eQTL locus contributing more to the susceptibility of lung cancer
Long noncoding RNAs (ncRNAs), involved in cancer biology, contributing to essential cancer cell functions such as proliferation, invasion, and metastasis, have received increasing attention recently.
The Human Zinc ribbon domain containing 1 (ZNRD1) has been confirmed to be involved in carcinogenesis and development of multiple cancers.
ZNRD1-AS1, a lncRNA in the upstream region of ZNRD1 which could down-regulate the expression of ZNRD1, has been identified as a possible component in carcinogenesis. The underlying relations of ZNRD1-AS1 with lung cancer development and metastasis remain obscure.
Znrd1/ Rat Znrd1 ELISA Kit |
|||
ELI-52826r | Lifescience Market | 96 Tests | 1063.2 EUR |
ZNRD1 |
|||
CSB-CL885791HU1 | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
ZNRD1 |
|||
CSB-CL885791HU2 | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
ZNRD1 |
|||
CSB-CL885791HU3 | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
ZNRD1 |
|||
MBS200956-001mg | MyBiosource | 0.01mg | 225 EUR |
ZNRD1 |
|||
MBS200956-5x001mg | MyBiosource | 5x0.01mg | 765 EUR |
ZNRD1 |
|||
pro-1747 | ProSpec Tany | 5µg | 60 EUR |
ZNRD1 siRNA |
|||
20-abx941175 | Abbexa |
|
|
ZNRD1 siRNA |
|||
20-abx941176 | Abbexa |
|
|
ZNRD1 Antibody |
|||
ABD9455 | Lifescience Market | 100 ug | 525.6 EUR |
ZNRD1 Antibody |
|||
43369 | SAB | 100ul | 319 EUR |
ZNRD1 Antibody |
|||
43369-100ul | SAB | 100ul | 302.4 EUR |
ZNRD1 Antibody |
|||
1-CSB-PA885791HA01HU | Cusabio |
|
|
ZNRD1 Antibody |
|||
E043369 | EnoGene | 100μg/100μl | 255 EUR |
In the current study, we first evaluated the expression ZNRD1-AS1 and ZNRD1 among lung cancer tissues and corresponding normal tissues, which showed higher expression of ZNRD1-AS1 and lower expression of ZNRD1. To reveal the underlying mechanisms, we then investigated the associations between ZNRD1 eQTLs SNPs in ZNRD1-AS1 and risk of lung cancer in Han Chinese populations. G allele of SNP rs9261204 was significantly associated with an increased risk of lung cancer when compared with A allele (OR: 1.45; 95% CI: 1.19-1.75; P = 1.06 × 10-4).
A weaker, but similar effect was also observed in bladder cancer. SNP rs3757328 was also associated with increased risk of lung cancer (OR: 1.34; 95% CI: 1.07-1.67; P = 0.011). Our findings first confirmed the contribution of LncRNA ZNRD1-AS1 to the development of lung cancer in Asian population.